BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A (Q35664516)
Jump to navigation
Jump to search
scientific article published on 15 June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A |
scientific article published on 15 June 2015 |
Statements
1 reference
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-A (English)
1 reference
Keith T Flaherty
1 reference
Judith B Manola
1 reference
Michael Pins
1 reference
David F McDermott
1 reference
Michael B Atkins
1 reference
Janice J Dutcher
1 reference
Daniel J George
1 reference
Kim A Margolin
1 reference
Robert S DiPaola
1 reference
15 June 2015
1 reference
1 reference
33
1 reference
21
1 reference
2384-2391
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference